OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free IDRSF Stock Alerts $2.64 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.64▼$2.6450-Day Range$1.40▼$2.6452-Week Range$1.40▼$11.35VolumeN/AAverage Volume3,347 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Idorsia alerts: Email Address Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Idorsia Stock (OTCMKTS:IDRSF)Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.Read More IDRSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IDRSF Stock News HeadlinesMarch 22, 2024 | bizjournals.comIdorsia gets FDA approval for high blood pressure drug TryvioMarch 22, 2024 | seekingalpha.comIdorsia: Aprocitentan Approval Is A Vital NewsMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 22, 2024 | globenewswire.comIdorsia thanks Guy Braunstein for his years of service as he retiresMarch 20, 2024 | msn.comFDA approves Idorsia’s once-daily antihypertensive TryvioMarch 20, 2024 | msn.comIdorsia gets FDA approval for hypertension drug TryvioMarch 20, 2024 | finance.yahoo.comIdorsia Ltd (IDRSF) Stock Historical Prices & Data - Yahoo FinanceMarch 20, 2024 | globenewswire.comUS FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 8, 2024 | finance.yahoo.comWhat Does The Future Hold For Idorsia Ltd (VTX:IDIA)? These Analysts Have Been Cutting Their EstimatesMarch 7, 2024 | realmoney.thestreet.comKepler Cheuvreux gets more bullish on Idorsia, upgrades sharesFebruary 28, 2024 | markets.businessinsider.comViatris, Idorsia Announce Global Research And Development CollaborationFebruary 6, 2024 | markets.businessinsider.comHere's what to expect from Idorsia's earningsJanuary 10, 2024 | finance.yahoo.comIdorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creationDecember 6, 2023 | finance.yahoo.comIdorsia Ltd (VTX:IDIA) surges 19%; individual investors who own 41% shares profited along with insidersOctober 25, 2023 | msn.comIdorsia Q3 Review: Not The Quarter We ExpectedOctober 24, 2023 | msn.comIdorsia GAAP EPS of CHF0.96, revenue of CHF80MOctober 24, 2023 | finance.yahoo.comIdorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable valueOctober 24, 2023 | marketwatch.comIdorsia Shares Fall on Funding NeedsOctober 23, 2023 | finance.yahoo.comIdorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023September 15, 2023 | msn.comNICE recommends Idorsia’s chronic insomnia treatment for UK patientsSeptember 6, 2023 | uk.finance.yahoo.comIdorsia reacquires the world-wide rights to aprocitentanAugust 31, 2023 | finance.yahoo.comTausif ('Tosh') Butt to Join Idorsia Pharmaceuticals U.S. as President and General ManagerAugust 25, 2023 | finance.yahoo.comIdorsia Ltd (IDIA.SW)August 18, 2023 | uk.finance.yahoo.comAre Investors Undervaluing Idorsia Ltd (VTX:IDIA) By 38%?July 27, 2023 | msn.comIdorsia: Restructuring In PlaceJuly 27, 2023 | finance.yahoo.comAnalysts Have Just Cut Their Idorsia Ltd (VTX:IDIA) Revenue Estimates By 21%See More Headlines Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:IDRSF CUSIPN/A CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Jean-Paul Clozel M.D. (Age 69)CEO & Executive Director Comp: $1.57MMr. André C. Muller (Age 61)Executive VP & CFO Dr. Martine Clozel (Age 69)Executive VP & Chief Scientific Officer Mr. Andrew C. Weiss (Age 56)Senior VP and Head of Investor Relations & Corporate Communications Mr. Julien Gander L.L.M. (Age 45)Senior VP, Group General Counsel & Company Secretary Mr. Alexander Khatuntsev (Age 46)Senior VP & Head of Global Human Resources Dr. Guy Braunstein M.D. (Age 68)Executive VP & Chief Medical Officer Mr. Olivier Lambert (Age 58)Senior VP & Head of Technical Operations Mr. Markus A. Riederer (Age 62)Senior VP & Head of Drug Discovery Biology Mr. Christoph Boss (Age 56)Senior VP & Head of Drug Discovery Chemistry More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors IDRSF Stock Analysis - Frequently Asked Questions Should I buy or sell Idorsia stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last year. There are currently 4 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "strong sell" IDRSF shares. View IDRSF analyst ratings or view top-rated stocks. How have IDRSF shares performed in 2024? Idorsia's stock was trading at $2.45 on January 1st, 2024. Since then, IDRSF shares have increased by 7.8% and is now trading at $2.64. View the best growth stocks for 2024 here. Are investors shorting Idorsia? Idorsia saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 9,112,700 shares, a drop of 14.6% from the February 29th total of 10,667,300 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 91,127.0 days. View Idorsia's Short Interest. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IDRSF) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesThe 3rd Revolution in WarfareWeiss RatingsFed launches fourth dollar overhaulStansberry ResearchAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.